CRISPR THERAPEUTICS AG Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
CRISPR THERAPEUTICS AG (CRSP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 436.10 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-03
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 270.83K shares, a 48.85% decline year-over-year.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 165.27K shares, a 35.71% decline year-over-year.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 167.91K shares, a 11.14% decline year-over-year.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 251.62K shares, a 120.13% increase year-over-year.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 1.21M shares, a 107.26% increase from fiscal 2024.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 581.89K shares, a 49.14% decline from fiscal 2023.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 1.14M shares, a 36.23% increase from fiscal 2022.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 839.81K shares, a 27.21% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 270.83K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | 436.10K shares 10-Q · filed 2026-08-03 | 604.01K shares derived: sum of 3 quarters · filed 2026-08-03 | 855.63K shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 165.27K shares 10-Q · filed 2026-05-04 | 333.18K shares derived: sum of 2 quarters · filed 2026-05-04 | 584.80K shares derived: sum of 3 quarters · filed 2026-05-04 | 1.11M shares derived: sum of 4 quarters · filed 2026-05-04 |
| 2025-12-31 | 167.91K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | 419.53K shares derived: sum of 2 quarters · filed 2026-02-12 | 948.97K shares derived: sum of 3 quarters · filed 2026-02-12 | 1.21M shares 10-K · filed 2026-02-12 |
| 2025-09-30 | 251.62K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 781.06K shares derived: sum of 2 quarters · filed 2025-11-10 | 1.04M shares 10-Q · filed 2025-11-10 | 1.23M shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 529.44K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | 786.50K shares 10-Q · filed 2025-08-04 | 975.48K shares derived: sum of 3 quarters · filed 2025-08-04 | 1.09M shares derived: sum of 4 quarters · filed 2025-08-04 |
| 2025-03-31 | 257.06K shares 10-Q · filed 2025-05-06 | 446.03K shares derived: sum of 2 quarters · filed 2025-05-06 | 560.34K shares derived: sum of 3 quarters · filed 2025-05-06 | 619.99K shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 188.97K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | 303.28K shares derived: sum of 2 quarters · filed 2025-02-11 | 362.93K shares derived: sum of 3 quarters · filed 2025-02-11 | 581.89K shares 10-K · filed 2025-02-11 |
| 2024-09-30 | 114.31K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | 173.95K shares derived: sum of 2 quarters · filed 2024-11-05 | 392.92K shares 10-Q · filed 2024-11-05 | 661.38K shares derived: sum of 4 quarters · filed 2024-11-05 |
| 2024-06-30 | 59.65K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | 278.61K shares 10-Q · filed 2024-08-05 | 547.08K shares derived: sum of 3 quarters · filed 2024-08-05 | 731.87K shares derived: sum of 4 quarters · filed 2024-08-05 |
| 2024-03-31 | 218.96K shares 10-Q · filed 2024-05-08 | 487.43K shares derived: sum of 2 quarters · filed 2024-05-08 | 672.22K shares derived: sum of 3 quarters · filed 2024-05-08 | 972.07K shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 268.47K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | 453.26K shares derived: sum of 2 quarters · filed 2024-02-21 | 753.11K shares derived: sum of 3 quarters · filed 2024-02-21 | 1.14M shares 10-K · filed 2024-02-21 |
| 2023-09-30 | 184.79K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 484.64K shares derived: sum of 2 quarters · filed 2023-11-06 | 875.59K shares 10-Q · filed 2023-11-06 | 1.07M shares derived: sum of 4 quarters · filed 2023-11-06 |
| 2023-06-30 | 299.85K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 690.80K shares 10-Q · filed 2023-08-07 | 880.91K shares derived: sum of 3 quarters · filed 2023-08-07 | 1.06M shares derived: sum of 4 quarters · filed 2023-08-07 |
| 2023-03-31 | 390.95K shares 10-Q · filed 2023-05-08 | 581.06K shares derived: sum of 2 quarters · filed 2023-05-08 | 761.32K shares derived: sum of 3 quarters · filed 2023-05-08 | 1.08M shares derived: sum of 4 quarters · filed 2023-05-08 |
| 2022-12-31 | 190.11K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | 370.37K shares derived: sum of 2 quarters · filed 2023-02-21 | 688.38K shares derived: sum of 3 quarters · filed 2023-02-21 | 839.81K shares 10-K · filed 2023-02-21 |
| 2022-09-30 | 180.26K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | 498.26K shares derived: sum of 2 quarters · filed 2022-11-01 | 649.70K shares 10-Q · filed 2022-11-01 | 929.95K shares derived: sum of 4 quarters · filed 2022-11-01 |
| 2022-06-30 | 318.01K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 469.44K shares 10-Q · filed 2022-08-08 | 749.69K shares derived: sum of 3 quarters · filed 2022-08-08 | 988.27K shares derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | 151.43K shares 10-Q · filed 2022-05-09 | 431.69K shares derived: sum of 2 quarters · filed 2022-05-09 | 670.26K shares derived: sum of 3 quarters · filed 2022-05-09 | 742.21K shares derived: sum of 4 quarters · filed 2022-05-09 |
| 2021-12-31 | 280.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | 518.83K shares derived: sum of 2 quarters · filed 2022-02-15 | 590.78K shares derived: sum of 3 quarters · filed 2022-02-15 | 660.18K shares 10-K · filed 2022-02-15 |
| 2021-09-30 | 238.58K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | 310.53K shares derived: sum of 2 quarters · filed 2021-11-03 | 379.93K shares 10-Q · filed 2021-11-03 | 418.37K shares derived: sum of 4 quarters · filed 2021-11-03 |
| 2021-06-30 | 71.95K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | 141.35K shares 10-Q · filed 2021-07-29 | 179.79K shares derived: sum of 3 quarters · filed 2021-07-29 | 239.35K shares derived: sum of 4 quarters · filed 2021-07-29 |
| 2021-03-31 | 69.40K shares 10-Q · filed 2021-04-27 | 107.85K shares derived: sum of 2 quarters · filed 2021-04-27 | 167.41K shares derived: sum of 3 quarters · filed 2021-04-27 | 328.79K shares derived: sum of 4 quarters · filed 2021-04-27 |
| 2020-12-31 | 38.44K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | 98.00K shares derived: sum of 2 quarters · filed 2021-02-16 | 259.38K shares derived: sum of 3 quarters · filed 2021-02-16 | 345.50K shares 10-K · filed 2021-02-16 |
| 2020-09-30 | 59.56K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | 220.94K shares derived: sum of 2 quarters · filed 2020-10-28 | 307.05K shares 10-Q · filed 2020-10-28 | 529.05K shares derived: sum of 4 quarters · filed 2020-10-28 |
| 2020-06-30 | 161.38K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-27 | 247.49K shares 10-Q · filed 2020-07-27 | 469.49K shares derived: sum of 3 quarters · filed 2020-07-27 | 627.99K shares derived: sum of 4 quarters · filed 2020-07-27 |
| 2020-03-31 | 86.11K shares 10-Q · filed 2020-04-28 | 308.11K shares derived: sum of 2 quarters · filed 2020-04-28 | 466.61K shares derived: sum of 3 quarters · filed 2020-04-28 | 591.57K shares derived: sum of 4 quarters · filed 2020-04-28 |
| 2019-12-31 | 221.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | 380.50K shares derived: sum of 2 quarters · filed 2020-02-12 | 505.45K shares derived: sum of 3 quarters · filed 2020-02-12 | 559.01K shares 10-K · filed 2020-02-12 |
| 2019-09-30 | 158.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-28 | 283.46K shares derived: sum of 2 quarters · filed 2019-10-28 | 337.02K shares 10-Q · filed 2019-10-28 | |
| 2019-06-30 | 124.96K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | 178.52K shares 10-Q · filed 2019-07-29 | ||
| 2019-03-31 | 53.56K shares 10-Q · filed 2019-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |